[ CAS No. 65-49-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}

Cat. No.: {[proInfo.prAm]}

2D 3D

Structure of 65-49-6 * Storage: {[proInfo.prStorage]}

Purity	Size	Price	VIP Price	USA Stock *0-1 Day	Global Stock *5-7 Days	Quantity
{[ item.p_purity ]}	{[ item.pr_size ]}	Inquiry	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,1,item.pr_is_large_size_no_price) ]}	{[ getRatePrice(item.pr_usd, 1,1,item.pr_is_large_size_no_price) ]}	Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate,item.pr_is_large_size_no_price) ]}	{[ item.pr_usastock ]}		{[ item.pr_chinastock ]}	{[ item.pr_remark ]}	Login		Inquiry

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

For Research Only 120K+ Compounds Competitive Price 1-2 Day Shipping

Quality Control of [ 65-49-6 ]

COA NMR CNMR HPLC LC-MS

Related Doc. of [ 65-49-6 ]

SDS Specification

Alternatived Products of [ 65-49-6 ]

Product Citations

Synthesis and biological evaluation of orally active prodrugs and analogs of para-aminosalicylic acid (PAS)

Pooja V. Hegde ; Michael D. Howe ; Matthew D. Zimmerman , et al. Eur. J. Med. Chem.,2022,232,114201. DOI: 10.1016/j.ejmech.2022.114201 PubMed ID: 35219151

Abstract: Tuberculosis (TB) is one of the world's most deadly infectious diseases resulting in nearly 1.3 million deaths annually and infecting nearly one-quarter of the population. para-Aminosalicylic acid (PAS), an important second-line agent for treating drug-resistant Mycobacterium tuberculosis, has moderate bioavailability and rapid clearance that necessitate high daily doses of up to 12 g per day, which in turn causes severe gastrointestinal disturbances presumably by disruption of gut microbiota and host epithelial cells. We first synthesized a series of alkyl, acyloxy and alkyloxycarbonyloxyalkyl ester prodrugs to increase the oral bioavailability and thereby prevent intestinal accumulation as well as undesirable bioactivation by the gut microbiome to non-natural folate species that exhibit cytotoxicity. The pivoxyl prodrug of PAS was superior to all of the prodrugs examined and showed nearly quantitative absorption. While the conceptually simple prodrug approach improved the oral bioavailability of PAS, it did not address the intrinsic rapid clearance of PAS mediated by N-acetyltransferase-1 (NAT-1). Thus, we next modified the PAS scaffold to reduce NAT-1 catalyzed inactivation by introduction of groups to sterically block N-acetylation and fluorination of the aryl ring of PAS to attenuate N-acetylation by electronically deactivating the para-amino group. Among the mono-fluorinated analogs prepared, 5-fluoro-PAS, exhibited the best activity and an 11-fold decreased rate of inactivation by NAT-1 that translated to a 5-fold improved exposure as measured by area-under-the-curve (AUC) following oral dosing to CD-1 mice. The pivoxyl prodrug and fluorination at the 5-position of PAS address the primary limitations of PAS and have the potential to revitalize this second-line TB drug.

Keywords: Tuberculosis ; para-Aminosalicylic acid (PAS) ; Prodrug ; Fluorination ; Metabolism ; N-acetyltransferase

Purchased from AmBeed: 65-49-6 ; 17455-13-9 ; 80841-78-7 ; 4136-97-4 ; 98298-66-9 ; 4093-28-1 ; 35180-01-9 ; 184033-42-9 ; 75-07-0 ; 40258-80-8 ; 6059-17-2 ; 66761-27-1 ; 475150-68-6 ; 75-30-9 ; 3282-30-2 ; 80841-79-8 ; 84089-73-6 ; 6952-12-1 ...More

Product Details of [ 65-49-6 ]

CAS No. :	65-49-6	MDL No. :
Formula :	C₇H₇NO₃	Boiling Point :	-
Linear Structure Formula :	NH₂C₆H₃(OH)CO₂H	InChI Key :	WUBBRNOQWQTFEX-UHFFFAOYSA-N
M.W :	153.14	Pubchem ID :	4649
Synonyms :	4-ASA;4-aminosalicylate;Sanipirol-4;PAS;NSC 211698;NSC 2083;p-Aminosalicylic Acid;Aminosalicylic acid;Para-aminosalicylic acid	Chemical Name :	4-Amino-2-hydroxybenzoic acid

Calculated chemistry of [ 65-49-6 ] Expand+

Physicochemical Properties

Num. heavy atoms :	11
Num. arom. heavy atoms :	6
Fraction Csp3 :	0.0
Num. rotatable bonds :	1
Num. H-bond acceptors :	3.0
Num. H-bond donors :	3.0
Molar Refractivity :	39.83
TPSA :	83.55 ?2

Pharmacokinetics

GI absorption :	High
BBB permeant :	No
P-gp substrate :	No
CYP1A2 inhibitor :	No
CYP2C19 inhibitor :	No
CYP2C9 inhibitor :	No
CYP2D6 inhibitor :	No
CYP3A4 inhibitor :	No
Log Kp (skin permeation) :	-6.3 cm/s

Lipophilicity

Log Po/w (iLOGP) :	0.84
Log Po/w (XLOGP3) :	1.32
Log Po/w (WLOGP) :	0.68
Log Po/w (MLOGP) :	-0.7
Log Po/w (SILICOS-IT) :	0.02
Consensus Log Po/w :	0.43

Druglikeness

Lipinski :	0.0
Ghose :	None
Veber :	0.0
Egan :	0.0
Muegge :	1.0
Bioavailability Score :	0.56

Water Solubility

Log S (ESOL) :	-1.96
Solubility :	1.68 mg/ml ; 0.011 mol/l
Class :	Very soluble
Log S (Ali) :	-2.68
Solubility :	0.323 mg/ml ; 0.00211 mol/l
Class :	Soluble
Log S (SILICOS-IT) :	-0.82
Solubility :	23.1 mg/ml ; 0.151 mol/l
Class :	Soluble

Medicinal Chemistry

PAINS :	0.0 alert
Brenk :	1.0 alert
Leadlikeness :	1.0
Synthetic accessibility :	1.04

Safety of [ 65-49-6 ]

Signal Word:	Warning	Class:	N/A
Precautionary Statements:	P305+P351+P338	UN#:	N/A
Hazard Statements:	H319	Packing Group:	N/A
GHS Pictogram:

Application In Synthesis of [ 65-49-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

Upstream synthesis route of [ 65-49-6 ]
Downstream synthetic route of [ 65-49-6 ]

[ 65-49-6 ] Synthesis Path-Upstream 1~1

1
[ 65-49-6 ]
[ 123654-26-2 ]

Reference： [1] Patent: CN107337658, 2017, A,

[ 65-49-6 ] Synthesis Path-Downstream 1~9

1
[ 65-49-6 ]
[ 16870-28-3 ]

Yield	Reaction Conditions	Operation in experiment
85 - 90%		Step A: 4-Aminosalicylic acid (4.0 g, 26 mmol) was suspended in H2SO4 (26 mL, 2.7M) at -50C. Sodium nitrite (1.8 g, 26.1 mmol) in H2O (6.5 mL) was cooled to ice bath temperature and was added dropwise to the aminosalicylic acid mixture over 5 minutes. The resulting suspension was stirred at -5 C for 15 minutes. A solution of KI (6.8 g, 41 mmol) in H2SO4 (13 mL, IM) was added dropwise to the diazonium salt, with considerable evolution of N2. The reaction mixture was heated at 7O0C for 20 minutes. The reaction mixture was then partitioned between H2O and EtOAc. The organic layer was dried and concentrated. Purification by silica gel chromatography (7/3, hexanes/acetone, 1% acetic acid) yielded 4-iodosalicylic acid (5.33g, 85-90% pure).
39.8%		In a 0.5 L 3 necked flask, 4-aminosalicylic acid 45 (15.3 g, 100 mmol) was mixed with H2O (100 ml), Conc. H2SO4 (14 ml, 25.8 g, 263 mmol). The mixture was stirred and cooled to 3-5 C. and diazotated by gradual addition of cold solution of NaNO2 (6.9 g, 100 mmol) in 20 ml water with control with iodine:starch paper of excess NaNO2. Dark solution was obtained. The diazotated solution was added to cold solution of KI (26 g, 156.6 mmol) in 25 ml 1N H2SO4. After 1 min, strong and rapid evolution of nitrogen was observed without heating. Ether (10-20 ml) was added to destroy the foam. The beaker with reaction mixture was heated at 75-80 C. for 10 min. The precipitate was filtered and washed with water and dried in air to obtain 17 g of raw product, which was purified by column chromatography: 340 g SiO2, 2% MeOH in CHCl3. 10.5 g, Yield: 39.8%.
35%.	With potassium iodide; sodium nitrite;copper(I) iodide; In sulfuric acid; water;	(b) Preparation of 2-hydroxy-4-iodobenzoic acid: To 20% sulfuric acid solution (650 ml) were added 4-amino-2-hydroxybenzoic acid and 200 ml of 20% sulfuric acid solution. The solution was cooled to -10 C. and a solution of sodium nitrite (47 g, 0.34 mol) in water (100 ml) was added over 5 hours. The solution obtained was added dropwise to a suspension of potassium iodide (69.5 g, 0.42 mol) and copper(I) iodide (69.5 g, 0.36 mol) in 370 ml of 20% sulfuric acid. The mixture was stirred for 36 hours at room temperature and was then filtered. The filtrate was extracted with ethyl acetate, washed twice with saturated sodium sulfite solution and twice with water. The organic phase was concentrated on a rotary evaporator under vacuum at 40 C. The properties of the final product were as follows: White solid. Mass: 24.25 g. Yield: 35%. m.p.: 192 C. 1 H NMR (DMSO, 250 MHz): 7.17 (1H, Ar, d, J=8.25 Hz), 7.25 (1H, Ar, s), 7.42 (1H, Ar, d, J=8.25 Hz).

		A suspension of 4-aminosalicylic acid (60.6 g) , water (240 mL), C-H2SO4 (90 mL) and acetic acid (240 mL) was cooled with an ice-bath. A solution of sodium nitrite (30.0 g) in water (60 mL) was added dropwise to the suspension over 30 min and the mixture was stirred at 00C for 1 hr. Then a solution of potassium iodide (200 g) in water (160 mL) was added dropwise over 30 min and the cooling-bath was removed. The mixture was stirred at room temperature for 20 hr, diluted with water and extracted with ethyl acetate (three times) . The extracts were combined, washed with 5% Na2S2Oa solution and brine, dried over MgSO4 and concentrated. The residue was suspended in acetonitrile and collected by filtration to give the title compound as a powder (35.0 g) .1H-NMR (300 MHz, DMSO-d6) delta: 7.30 (dd, J = 8.1, 1.8 Hz, IH), 7.38 (d, J = 1.8 Hz, IH), 7.51 (d, J = 8.1 Hz, IH).
		A sample of 4-amino-2-hydroxysalicylic acid (10 g, 65.3 mmol) is charged to a 2 liter Erlenmeyer flask equipped with a large stir bar, cooled in an ice/water bath and treated with concentrated sulfuric acid (20 mL) and enough water to make a free flowing suspension (50 mL). After stirring for 20 minutes, the reaction is treated with a solution of sodium nitrite (4.55 g, 66.0 mmol) in water (20 mL) over the course of 10 minutes. After stirring an additional 3 minutes, the reaction is treated with a solution of potassium iodide (16.9 g, 101 mmol) in water (30 mL) over the course of 15 minutes. The cooling bath is removed and the reaction is carefully monitored and stirred as it generates a significant amount of nitrogen gas. After the reaction subsides, it is briefly heated to 70 C. after which it is allowed to cool to room temperature and sit overnight. The resulting solid is collected by filtration, washed with water and dried to give crude 2-hydroxy-4-iodo-benzoic acid that is used in the next reaction without further purification: ESMS m/z 265.0 (M+H+).
		Example 1 Synthesis of 4-[2-(4-carboxy-3-hydroxy-phenyl)ethynyl]-2-hydroxy-benzoic acid (I) Synthesis of Compound 2 11.0 g (72.0 mmol) of 4-aminosalicylic acid (1) was taken in 110.0 ml 50% H2SO4 and cooled to -5 C. and stirred for 20 minutes. To this NaNO2 solution (5.5 g, 80 mmol of NaNO2 in 6.5 ml deionized water) was added drop wise maintaining temperature below 0 C. and stirred for 20 minutes. This diazonium salt solution was added drop wise to the freshly prepared CuI solution* at -5 C. After addition, temperature of the reaction mixture was raised to room temperature and then heated to 90 C. for 1 h. After completion of reaction, the reaction mixture was cooled to room temperature and filtered to obtain yellow solid which was washed with water and dried. This solid was dissolved in hot ethanol and filtered. The inorganic residue remained was washed with ethanol and the filtrate was evaporated to dryness under vacuum to obtain 16.0 g of crude Compound 2 as a brown solid. *(CuI solution: 17.95 g (72.0 mmol) CuSO4.5H2O, 5.5 g (86.0 mmol) Cu-powder and 55.0 g (332.0 mmol) KI were taken in 100.0 ml deionized water. To this 100.0 ml 20% H2SO4 was added with constant stirring. Reaction mixture was allowed to stirred at room temperature for 1 h and then it was cooled to -5 C. CuI gets precipitated out as off-white solid. The above solution of CuI is directly used for the preparation of Compound 2. Yield: 84.6% Analysis: 1H NMR (300 MHz, MeOD): delta 7.48 (d, 1H); 7.24 (d, 1H); 7.19 (dd, 1H). MS (m/z): 263 (M+-H)
		Example 1 Synthesis of 4-[2-(4-carboxy-3-hydroxy-phenyl)ethynyl]-2-hydroxy-benzoic acid (I) Synthesis of Compound 2 11.0 g (72.0 mmol) of 4-aminosalicylic acid (1) was taken in 110.0 ml 50% H2SO4 and cooled to -5 C. and stirred for 20 minutes. To this NaNO2 solution (5.5 g, 80 mmol of NaNO2 in 6.5 ml deionized water) was added drop wise maintaining temperature below 0 C. and stirred for 20 minutes. This diazonium salt solution was added drop wise to the freshly prepared CuI solution* at -5 C. After addition, temperature of the reaction mixture was raised to room temperature and then heated to 90 C. for 1 h. After completion of reaction, the reaction mixture was cooled to room temperature and filtered to obtain yellow solid which was washed with water and dried. This solid was dissolved in hot ethanol and filtered. The inorganic residue remained was washed with ethanol and the filtrate was evaporated to dryness under vacuum to obtain 16.0 g of crude Compound 2 as a brown solid. *(CuI solution: 17.95 g (72.0 mmol) CuSO4.5H2O, 5.5 g (86.0 mmol) Cu-powder and 55.0 g (332.0 mmol) KI were taken in 100.0 ml deionized water. To this 100.0 ml 20% H2SO4 was added with constant stirring. Reaction mixture was allowed to stirred at room temperature for 1 h and then it was cooled to -5 C. CuI gets precipitated out as off-white solid. The above solution of CuI is directly used for the preparation of Compound 2. Yield: 84.6% Analysis: 1H NMR (300 MHz, MeOD): delta 7.48 (d, 1H); 7.24 (d, 1H); 7.19 (dd, 1H). MS (m/z): 263 (M+-H)

Reference： [1]Patent: WO2006/19831,2006,A1 .Location in patent: Page/Page column 445
[2]Russian Journal of Organic Chemistry,2008,vol. 44,p. 1243 - 1244
[3]Il Farmaco,2003,vol. 58,p. 173 - 183
[4]Patent: US2016/2269,2016,A1 .Location in patent: Paragraph 0236; 0237
[5]Nippon Kagaku Zasshi,1957,vol. 78,p. 1608,1612
Chem.Abstr.,1959,p. 21342
[6]Journal of Medicinal Chemistry,1997,vol. 40,p. 2474 - 2481
[7]Patent: US5849798,1998,A
[8]Patent: WO2007/77961,2007,A2 .Location in patent: Page/Page column 320
[9]Patent: US2008/194668,2008,A1 .Location in patent: Page/Page column 7
[10]Bioorganic and Medicinal Chemistry,2009,vol. 17,p. 6567 - 6582
[11]Patent: US2014/81044,2014,A1 .Location in patent: Paragraph 0145-0149
[12]Patent: WO2014/45135,2014,A1 .Location in patent: Page/Page column 16

2
[ 64-17-5 ]
[ 42059-80-3 ]
[ 65-49-6 ]
3-(4-carboxy-3-hydroxyphenyl)aminomethylene-2-ethoxy-6-nitrochroman-4-one [ No CAS ]

Reference： [1]Il Farmaco,1995,vol. 50,p. 885 - 888
[2]Tetrahedron,2001,vol. 57,p. 3455 - 3464
[3]Tetrahedron,2001,vol. 57,p. 3455 - 3464

3
[ 42059-80-3 ]
[ 65-49-6 ]
[ 67-63-0 ]
3-(4-carboxy-3-hydroxyphenyl)aminomethylene-6-nitro-2-i-propyloxychroman-4-one [ No CAS ]

Reference： [1]Il Farmaco,1995,vol. 50,p. 885 - 888
[2]Tetrahedron,2001,vol. 57,p. 3455 - 3464

4
[ 1184-90-3 ]
[ 65-49-6 ]
4-guanidino-2-hydroxybenzoic acid [ No CAS ]

Reference： [1]Journal of Chemical Crystallography,2005,vol. 35,p. 561 - 564

5
[ 65-49-6 ]
[ 71675-87-1 ]

Reference： [1]Patent: WO2011/158084,2011,A1
[2]Patent: WO2011/158084,2011,A1

6
[ 100-39-0 ]
[ 65-49-6 ]
[ 19008-43-6 ]

Yield	Reaction Conditions	Operation in experiment
82%		General Procedure b (Di-benzylation of the salicylic acid). To a stirred solution of 4- aminosalicyclic acid (6.00 g, 39.2 mmol) in DMF (0.1 M) at 0 C, was added KOtBu (4.84 g, 43.2 mmol). After 15 mins, benzyl bromide (5.14 mL, 43.2 mmol) was added drop-wise. The suspension was allowed to stir at R.T. for a further 4 hrs before the reaction vessel was againcooled to 0C. A further 1.1 eqs of K1OBu (2.84g, 43.2 mmol) were added prior to the drop- wise addition of benzyl bromide (5.14 mL, 43.2 mmol). The reaction was then stirred overnight before quenching with 1120. The solution was then repeatedly extracted with ethyl acetate and the organics combined. The organics were then washed with 1120 and brine then concentrated, dried over Na2SO4 and concentrated in vacuo. The resulting residue waspurified using the Biotage Isolera automated column chromotographer in a gradient of EtOAc and Hexane and then dried under reduced pressure.Example 7 - Compound 3c benzyl 4-aminobenzoate Chemical Formula: C 4H13N02 Molecular Weight: 227.26 Compound 3c was synthesized according to general procedure b, yielding the final product 3c as a white solid (82%) .<5H (400 MHz, d-COCh) 4.25 (brs, 2H, NH2), 5.38 (s, 2H, CH), 6.63 (d, J = 8.2 Hz, 2H, CH), 7.33-7.51 (m, 5H, CH), 7.96 (d, J = 8.2 Hz, 2H,CH) ; Sc (100 MHz, d-COC ) 66.1 , 1 13.7, 1 18.9, 127.9, 128.0, 128.7, 131.7, 136.6, 151.5, 166.6; LRMS (ES+) Calcd for [Ci4HBN02 + Na] 250.08 found 250.07.

Reference： [1]Patent: WO2013/177534,2013,A2 .Location in patent: Page/Page column 54

7
[ 313368-91-1 ]
[ 65-49-6 ]
1-(4-fluorophenyl)-4-((6bR,10aS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H-pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalin-8-yl)butan-1-one 4-aminosalicylate [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In methanol; dibutyl ether;	A 4-aminosalicylate salt is obtained in screening in a precipitation experiment using methanol. This experiment is repeated at a gram scale. The JTJ-007 free base and 4-aminosalicylic acid (ratio 1:1) are dissolved in methanol (5 mL) and then dibutylether is added as an anti-solvent (lOmL). The mixture is shaken at room temperature and a yellow solid is precipitated. The yellow solid is filtered, dried and analyzed by XRPD. XRPD analysis shows the 4-aminosalicilate salt to be crystalline.

Reference： [1]Patent: WO2017/172784,2017,A1 .Location in patent: Paragraph 0058

8
[ 65-49-6 ]
[ 417721-36-9 ]

Reference： [1]Patent: CN107629001,2018,A
[2]Patent: CN109456267,2019,A

9
[ 7749-47-5 ]
[ 65-49-6 ]
C₆H₉N₃O*C₇H₇NO₃ [ No CAS ]

Yield	Reaction Conditions	Operation in experiment
	In methanol; for 0.5h;Heating;	General procedure: The title salts were synthesized by the reaction of 1:1 stoichiometricmixtures of 2-amino-4-methoxy-6-methylpyrimidine(34.79 mg, 0.25 mmol) with 4-aminosalicylic acid (38.28 mg,0.25 mmol) or 5-chlorosalicylic acid (43.14 mg, 0.25 mmol) inhot methanol solution (20 ml), after warming over a water bathfor 30 min. The solutions were cooled and kept at roomtemperature.Within a few days, block-shaped brown crystals ofsalt I and colourless needle-shaped crystals of salt II wereobtained by slow evaporation at room temperature. Bothcrystals were suitable for single-crystal X-ray structure analysis

Reference： [1]Acta Crystallographica Section C: Structural Chemistry,2022,vol. 78,p. 181 - 191

Recommend Products

Same Skeleton Products

Related Products

Isomers

Technical Information

? Acidity of Phenols ? Alkyl Halide Occurrence ? Arndt-Eistert Homologation ? Chan-Lam Coupling Reaction ? Electrophilic Substitution of the Phenol Aromatic Ring ? Etherification Reaction of Phenolic Hydroxyl Group ? Halogenation of Phenols ? Hunsdiecker-Borodin Reaction ? Oxidation of Phenols ? Passerini Reaction ? Pechmann Coumarin Synthesis ? Preparation of Aldehydes and Ketones ? Preparation of Amines ? Preparation of Carboxylic Acids ? Reactions of Amines ? Reactions of Carboxylic Acids ? Reimer-Tiemann Reaction ? Schmidt Reaction ? Specialized Acylation Reagents-Ketenes ? Ugi Reaction

Historical Records

Ghs Precautionary Statements

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed
H304	May be fatal if swallowed and enters airways
H305	May be harmful if swallowed and enters airways
H310	Fatal in contact with skin
H311	Toxic in contact with skin
H312	Harmful in contact with skin
H313	May be harmful in contact with skin
H314	Causes severe skin burns and eye damage
H315	Causes skin irritation
H316	Causes mild skin irritation
H317	May cause an allergic skin reaction
H318	Causes serious eye damage
H319	Causes serious eye irritation
H320	Causes eye irritation
H330	Fatal if inhaled
H331	Toxic if inhaled
H332	Harmful if inhaled
H333	May be harmful if inhaled
H334	May cause allergy or asthma symptoms or breathing difficulties if inhaled
H335	May cause respiratory irritation
H336	May cause drowsiness or dizziness
H340	May cause genetic defects
H341	Suspected of causing genetic defects
H350	May cause cancer
H351	Suspected of causing cancer
H360	May damage fertility or the unborn child
H361	Suspected of damaging fertility or the unborn child
H361d	Suspected of damaging the unborn child
H362	May cause harm to breast-fed children
H370	Causes damage to organs
H371	May cause damage to organs
H372	Causes damage to organs through prolonged or repeated exposure
H373	May cause damage to organs through prolonged or repeated exposure
Environmental hazards
Code	Phrase
H400	Very toxic to aquatic life
H401	Toxic to aquatic life
H402	Harmful to aquatic life
H410	Very toxic to aquatic life with long-lasting effects
H411	Toxic to aquatic life with long-lasting effects
H412	Harmful to aquatic life with long-lasting effects
H413	May cause long-lasting harmful effects to aquatic life
H420	Harms public health and the environment by destroying ozone in the upper atmosphere

成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

[ CAS No. 65-49-6 ] {[proInfo.proName]}

Quality Control of [ 65-49-6 ]

Related Doc. of [ 65-49-6 ]

Product Citations

Product Details of [ 65-49-6 ]

Calculated chemistry of [ 65-49-6 ] Expand+

Physicochemical Properties

Pharmacokinetics

Lipophilicity

Druglikeness

Water Solubility

Medicinal Chemistry

Safety of [ 65-49-6 ]

Application In Synthesis of [ 65-49-6 ]

[ 65-49-6 ] Synthesis Path-Upstream 1~1

[ 65-49-6 ] Synthesis Path-Downstream 1~9

Technical Information

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry